These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 310748)

  • 41. Procainamide and N-acetylprocainamide kinetics investigated simultaneously with stable isotope methodology.
    Dutcher JS; Strong JM; Lucas SV; Lee WK; Atkinson AJ
    Clin Pharmacol Ther; 1977 Oct; 22(4):447-57. PubMed ID: 902457
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Procainamide pharmacokinetics during extracorporeal membrane oxygenation.
    Vollmer NJ; Wittwer ED; Rosenbaum AN; Wieruszewski PM
    Perfusion; 2023 Mar; 38(2):409-413. PubMed ID: 34617854
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Hemodynamic effects of N-acetylprocainamide in man: comparison with other antiarrhythmic drugs.
    Josephson MA; Singh BN
    Angiology; 1986 Dec; 37(12 Pt 2):950-8. PubMed ID: 2433969
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The quantitative disposition of procainamide and N-acetylprocainamide in the rat.
    Schneck DW; Grove K; Dewitt FO; Shiroff RA; Hayes AH
    J Pharmacol Exp Ther; 1978 Jan; 204(1):219-25. PubMed ID: 619132
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Bioavailability of N-acetylprocainamide from mixed diet in rats.
    Kamath BL; Yacobi A; Gupta SD; Stampfli H; Durrani M; Lai CM
    Res Commun Chem Pathol Pharmacol; 1981 May; 32(2):299-308. PubMed ID: 6166034
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmacokinetic studies of procainamide (PA) and N-acetylprocainamide (NAPA) in healthy subjects.
    Wierzchowiecki M; Michałowska D; Lowicki Z; Ochotny R; Grześkowiak A; Tomaszkiewicz T
    Int J Clin Pharmacol Ther Toxicol; 1980 Jun; 18(6):272-6. PubMed ID: 6161089
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Theoretical basis for interest in acetylprocainamide and clinical experiences with this new antiarrhythmic agent.
    Drayer D; Kluger J; Reidenberg M; Lahita R
    Drug Metab Rev; 1979; 10(2):239-46. PubMed ID: 95247
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The reversible biotransformation of N-acetylprocainamide in the rhesus monkey.
    Ding TL; Lin ET; Benet LZ
    Arzneimittelforschung; 1978; 28(2):281-3. PubMed ID: 416831
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The discordant influences of infarct healing on the electrophysiologic effects of procainamide and N-acetylprocainamide.
    Nelson SD; Coyne KS; Meimer J
    J Pharmacol Exp Ther; 1995 Apr; 273(1):315-9. PubMed ID: 7536244
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Trimethoprim inhibition of the renal clearance of procainamide and N-acetylprocainamide.
    Vlasses PH; Kosoglou T; Chase SL; Greenspon AJ; Lottes S; Andress E; Ferguson RK; Rocci ML
    Arch Intern Med; 1989 Jun; 149(6):1350-3. PubMed ID: 2471472
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Absolute bioavailability in man of N-acetylprocainamide determined by a novel stable isotope method.
    Strong JM; Dutcher JS; Lee WK; Atkinson AJ
    Clin Pharmacol Ther; 1975 Nov; 18(5 Pt 1):613-22. PubMed ID: 1183141
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effective plasma concentration of N-acetylprocainamide in rats.
    Yacobi A; Krasula RW; Lai CM; Kamath BL
    Res Commun Chem Pathol Pharmacol; 1979 Apr; 24(1):197-200. PubMed ID: 432435
    [TBL] [Abstract][Full Text] [Related]  

  • 53. N-Acetylprocainamide pharmacokinetics in functionally anephric patients before and after perturbation by hemodialysis.
    Stec GP; Atkinson AJ; Nevin MJ; Thenot JP; Ruo TI; Gibson TP; Ivanovich P; del Greco F
    Clin Pharmacol Ther; 1979 Nov; 26(5):618-28. PubMed ID: 91468
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Procainamide and phenytoin. Comparative study of their antiarrhythmic effects at apparent therapeutic plasma levels.
    Karlsson E
    Br Heart J; 1975 Jul; 37(7):731-40. PubMed ID: 1098684
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Polymorphic acetylation procainamide in man.
    Reidenberg MM; Drayer DE; Levy M; Warner H
    Clin Pharmacol Ther; 1975 Jun; 17(6):722-30. PubMed ID: 237647
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The assessment of an antiarrhythmic agent, sustained-release procainamide, with the aid of Holter monitoring.
    Bauer GE; Mitchell AS; Bates F; Hellestrand K
    Med J Aust; 1977 Nov; 2(22):733-5. PubMed ID: 347229
    [TBL] [Abstract][Full Text] [Related]  

  • 57. N-Acetylprocainamide levels in patients with end-stage renal failure.
    Gibson TP; Matusik EJ; Briggs WA
    Clin Pharmacol Ther; 1976 Feb; 19(2):206-12. PubMed ID: 1261157
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Procainamide-cimetidine drug interaction in elderly male patients.
    Bauer LA; Black D; Gensler A
    J Am Geriatr Soc; 1990 Apr; 38(4):467-9. PubMed ID: 2329253
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Disposition of procainamide and N-acetylprocainamide in protein-calorie malnutrition.
    Jung D; Nanavaty M; Prasad P
    Drug Metab Dispos; 1985; 13(3):359-63. PubMed ID: 2410212
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Monitoring of procainamide and N-acetylprocainamide concentration in saliva after oral administration of procainamide.
    Koike Y; Mineshita S; Uchiyama Y; Shudo I; Shimamura K; Togashi H; Saito H
    Am J Ther; 1996 Oct; 3(10):708-14. PubMed ID: 11862226
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.